Getein Biotech Inc (603387) - Total Liabilities

Latest as of March 2026: CN¥765.68 Million CNY ≈ $112.04 Million USD

Based on the latest financial reports, Getein Biotech Inc (603387) has total liabilities worth CN¥765.68 Million CNY (≈ $112.04 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 603387 year-over-year net asset growth to track the company's year-over-year net asset growth rate.

Getein Biotech Inc - Total Liabilities Trend (2012–2025)

This chart illustrates how Getein Biotech Inc's total liabilities have evolved over time, based on quarterly financial data. See how much free cash does Getein Biotech Inc generate to measure how efficiently the company converts operating cash flow to free cash.

Getein Biotech Inc Competitors by Total Liabilities

The table below lists competitors of Getein Biotech Inc ranked by their total liabilities.

Company Country Total Liabilities
Washington Trust Bancorp Inc
NASDAQ:WASH
USA $6.08 Billion
MCAN Mortgage Corporation
TO:MKP
Canada CA$6.00 Billion
Shenzhen Sea Star Technology
SHE:002137
China CN¥336.29 Million
JSE Limited
JSE:JSE
South Africa ZAC62.48 Billion
Weebit Nano Ltd
AU:WBT
Australia AU$6.77 Million
Beijing North Star Co Ltd Class A
SHG:601588
China CN¥34.01 Billion
Shenzhen Xunjiexing Technology Corp. Ltd.
SHG:688655
China CN¥835.93 Million
Zhejiang Zhongcheng Packing Material Co Ltd
SHE:002522
China CN¥1.26 Billion

Liability Composition Analysis (2012–2025)

This chart breaks down Getein Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Getein Biotech Inc (603387) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 3.21 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.27 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.21 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Getein Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Getein Biotech Inc (2012–2025)

The table below shows the annual total liabilities of Getein Biotech Inc from 2012 to 2025.

Year Total Liabilities Change
2025-12-31 CN¥896.55 Million
≈ $131.19 Million
-9.11%
2024-12-31 CN¥986.42 Million
≈ $144.34 Million
-4.27%
2023-12-31 CN¥1.03 Billion
≈ $150.78 Million
+1.73%
2022-12-31 CN¥1.01 Billion
≈ $148.21 Million
+17.24%
2021-12-31 CN¥863.90 Million
≈ $126.42 Million
+24.13%
2020-12-31 CN¥695.95 Million
≈ $101.84 Million
+113.49%
2019-12-31 CN¥325.98 Million
≈ $47.70 Million
+74.11%
2018-12-31 CN¥187.23 Million
≈ $27.40 Million
+57.50%
2017-12-31 CN¥118.87 Million
≈ $17.39 Million
+30.45%
2016-12-31 CN¥91.13 Million
≈ $13.33 Million
+53.21%
2015-12-31 CN¥59.48 Million
≈ $8.70 Million
+44.16%
2014-12-31 CN¥41.26 Million
≈ $6.04 Million
-41.41%
2013-12-31 CN¥70.42 Million
≈ $10.31 Million
+43.27%
2012-12-31 CN¥49.15 Million
≈ $7.19 Million
--

About Getein Biotech Inc

SHG:603387 China Medical Devices
Market Cap
$665.69 Million
CN¥4.55 Billion CNY
Market Cap Rank
#10790 Global
#2941 in China
Share Price
CN¥8.97
Change (1 day)
+0.79%
52-Week Range
CN¥7.52 - CN¥10.65
All Time High
CN¥21.49
About

Getein Biotech, Inc researches, develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. The company provides point-of-care detection, chemiluminescence detection, biochemical analysis, molecular testing, thrombus and hemostasis detection, blood cell analysis detection, urine analysis, quality control products, diagnostic raw materials, biochemical … Read more